Compare Global X SuperDividend ETF (SDIV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X SuperDividend ETF vs TG Therapeutics Inc — how do they compare? Global X SuperDividend ETF trades at $23.96 (market cap $1.17B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 7× Global X SuperDividend ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X SuperDividend ETF for 47 Days and TG Therapeutics Inc for 16 Days on average.
| SDIV | TGTX | |
|---|---|---|
Market Cap | $1.17B | $8.16B |
Volume | 387,692 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $26.34 | $59.06 |
52-Week Low | $22.90 | $26.94 |
Typical Hold Time | 47 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SDIV trades at $23.96, up 1.61% with a bearish technical outlook from moving averages. The ETF maintains an 8%+ dividend yield but faces significant price erosion, having lost 66% since inception according to Seeking Alpha (2026-09-11). Recent institutional buying includes Ameritas Advisory Services increasing its position by 92.6% in Q2 2026. Technical indicators show mixed signals with neutral oscillators but bearish moving averages and ADX readings.
SDIV offers high income potential but carries substantial principal risk. The fund's deep value approach lacks quality screening, leading to persistent underperformance versus global benchmarks. While monthly dividends attract income seekers, the erosion of capital requires careful risk assessment for long-term investors considering this high-yield strategy.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
